Understanding Factor V Leiden Mutation (FVL, Factor V Leiden Deficiency, Leiden Thrombophilia, factor 5 leiden) is crucial for accurate healthcare documentation and medical coding. This page provides information on diagnosing and managing Factor V Leiden, including relevant clinical findings, ICD-10 codes, and best practices for clinical documentation improvement (CDI) related to this inherited thrombophilia. Learn about the risks, symptoms, and genetic testing associated with Factor V Leiden Mutation for improved patient care and accurate medical records.
Also known as
Factor V Leiden mutation
Presence of the Factor V Leiden mutation, increasing risk of blood clots.
Personal history of other venous embolism and thrombosis
History of venous thromboembolism, which can be related to Factor V Leiden.
Other venous embolism and thrombosis of unspecified deep vessels of lower extremity
Venous thromboembolism in lower extremities, a possible complication of Factor V Leiden.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is Factor V Leiden mutation confirmed by testing?
When to use each related code
| Description |
|---|
| Inherited blood clotting disorder. |
| Inherited blood clotting disorder. |
| Acquired blood clotting disorder. |
Coding F5 mutation without specifying heterozygous or homozygous status (e.g., Z83.79 vs. Z83.718) impacts severity and risk assessment.
Lack of documentation confirming F5 Leiden diagnosis (e.g., genetic testing) can lead to inaccurate coding and denied claims.
Coding F5 Leiden without documented clinical manifestations or therapeutic implications (e.g., thrombosis) may raise medical necessity concerns.
Q: What are the recommended diagnostic testing procedures for identifying Factor V Leiden Mutation in patients with suspected thrombophilia?
A: Diagnosing Factor V Leiden Mutation, a prevalent inherited thrombophilia, involves specific laboratory testing procedures. The most common approach is the activated protein C resistance (APC-R) assay, which assesses the ability of activated protein C to inhibit Factor V. If the APC-R assay is positive, a genetic test for the Factor V Leiden mutation (specifically, the G1691A substitution in the Factor V gene) is performed to confirm the diagnosis. Other tests, such as a functional assay for activated protein C resistance or genetic sequencing, might be considered in specific situations, like when the APC-R assay is equivocal. Accurate diagnosis is crucial for appropriate management and risk stratification, which may include anticoagulation therapy for high-risk individuals. Explore how genetic testing technologies have improved the accuracy and efficiency of Factor V Leiden mutation diagnosis. Consider implementing a standardized diagnostic pathway in your practice to ensure timely and accurate identification of this common thrombophilia.
Q: How should I manage a patient with Factor V Leiden Mutation who is pregnant or planning pregnancy, considering the increased risk of venous thromboembolism?
A: Pregnancy significantly increases the risk of venous thromboembolism (VTE) in women with Factor V Leiden Mutation. Management strategies should be individualized based on the patient's risk factors, including prior VTE history, family history of VTE, and other thrombophilic conditions. Prophylactic anticoagulation with low molecular weight heparin (LMWH) is often recommended during pregnancy and the postpartum period for women with Factor V Leiden and a prior VTE or strong family history. Risk assessment tools, like the Caprini score, can be helpful in stratifying VTE risk and guiding management decisions. In patients with a history of recurrent VTE, continued anticoagulation throughout pregnancy may be necessary. Learn more about current guidelines and best practices for managing VTE risk in pregnant women with Factor V Leiden mutation. Consider implementing a comprehensive risk assessment protocol for all pregnant women to identify those requiring specialized thromboprophylaxis.
Patient presents with [mention reason for clinical encounter related to potential Factor V Leiden Mutation, e.g., deep vein thrombosis, pulmonary embolism, recurrent pregnancy loss, or family history of thrombophilia]. Assessment reveals [include relevant signs and symptoms, e.g., unilateral leg swelling, pain, shortness of breath, or history of pregnancy complications]. Differential diagnosis includes Factor V Leiden Mutation, other inherited thrombophilias (e.g., prothrombin gene mutation, protein C deficiency, protein S deficiency, antithrombin deficiency), acquired thrombophilia, and other causes of venous thromboembolism. Given the patient's presentation and risk factors, Factor V Leiden testing (activated protein C resistance or genetic testing for the F5 gene mutation) was ordered. Preliminary assessment suggests a possible diagnosis of Factor V Leiden Deficiency, also known as Leiden Thrombophilia or Factor 5 Leiden. This diagnosis is supported by [mention supporting clinical findings, family history, or preliminary test results]. Further evaluation is necessary to confirm the diagnosis and assess the extent of the thrombotic risk. Plan includes [mention specific diagnostic tests, e.g., confirmatory genetic testing for the Factor V Leiden mutation, APC resistance assay] and discussion of potential management strategies, which may include anticoagulation therapy (e.g., heparin, warfarin, direct oral anticoagulants DOACs) depending on the clinical context and patient's individual risk factors for venous thromboembolism VTE. Patient education provided regarding Factor V Leiden inheritance, risk factors for thrombosis, and preventative measures. Follow-up appointment scheduled to review test results, confirm the diagnosis of Factor V Leiden mutation, and discuss long-term management options, including thromboprophylaxis during high-risk periods (e.g., surgery, pregnancy). ICD-10 coding will be finalized upon confirmation of the diagnosis (e.g., D68.59 Other specified coagulation defects, Z86.711 Personal history of venous thromboembolism). Medical billing will reflect the services provided, including evaluation, testing, and patient education related to Factor V Leiden.